Monday 30th August 2021
|Text too small?|
Rua Bioscience announces its annual financial results for the 12 months ended 30 June 2021 (FY21). In FY21, Rua's focus has been on building solid foundations for growth – developing the partnerships, places, processes, and people it needs to create a sustainable medicinal cannabis business model.
Rua’s commitment to creating shareholder value has seen it working on two fronts - preparing to enter local and global medicinal cannabis markets by calendar year end 2021 / early 2022 and developing long-term opportunities across the medicinal cannabis value chain.
Rua Bioscience is a pharmaceutical company aiming to lead the production of cannabinoid-derived medicines. The Company has a focused and realistic export strategy, with a clear path to revenue and a view extending along the medicinal cannabis value chain. Proceeds from the IPO continue to fund Rua Bioscience's next growth stage, building long-term resilience and accelerating growth.
Please see the links below for details
No comments yet
21st January 2022 Morning Report
Trade Window Holdings Limited (NZX: TWL) TradeWindow and Mastercard teams up
Genesis Energy Limited (NZX: GNE) FY22 Q2 Performance Report
Seeka Limited (NZX: SEK) Seeka announces dividend of 13 cents per share
20th January 2022 Morning Report
Z Energy Limited (NZX: ZEL) Q3FY33 Operating Data
Smartpay Holdings Limited (NZX: SPY) Trading Update
Rua Bioscience Limited (NZX: RUA) Shareholders Approve Zalm Therapeutics Share Issue
Harmoney Corp Limited (NZX: HMY) HMY achieves cash NPAT profitability in 1HFY22
19th January 2022 Morning Report